Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis

Journal of Viral Hepatitis

Volumn 23, Issue 7, 2016, Pages 496-505

  Meissner, E G ^a,b,c   Kohli, A ^b,d   Virtaneva, K ^e   Sturdevant, D ^e   Martens, C ^e   Porcella, S F ^e   McHutchison, J G ^f   Masur, H ^d   Kottilil, S ^b,g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f GILEAD SCIENCES   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

Author keywords

cirrhosis; endogenous interferons; hepatitis C virus; interferon free therapy; treatment relapse

Indexed keywords

INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; MESSENGER RNA; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 130A; MICRORNA 141; MICRORNA 155; MICRORNA 192; MICRORNA 196; MICRORNA 199A; MICRORNA 208B; MICRORNA 21; MICRORNA 27A; MICRORNA 29; MICRORNA 296; MICRORNA 351; MICRORNA 431; MICRORNA 448; MICRORNA 499; MICRORNA 508; MICRORNA 99A; MICRORNA LET 7A; MICRORNA LET 7B; MICRORNA LET 7C; MICRORNA LET 7F; RADALBUVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDROPREVIR;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; IFN GENE; IFNA2 GENE; IFNA5 GENE; IFNB1 GENE; IFNG GENE; IFNL1 GENE; IFNL3 GENE; IFNL4 GENE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS REPLICATION;

EID: 84975152240     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12510     Document Type: Article

References (50)

1. Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015; 35(8): 1923–1933.
2. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417–2428.
3. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207–1217.
4. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365(11): 1014–1024.
5. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195–1206.
6. Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310(8): 804–811.
7. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993–2001.
8. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20): 1867–1877.
9. Gane EJ, Stedman CA, Hyland RH et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146(3): 736–743.
10. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483–1493.
11. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973–1982.
12. Meissner EG, Wu D, Osinusi A et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124(8): 3352–3363.
13. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLoS One 2013; 8(12): e84026.
14. Martin B, Hennecke N, Lohmann V et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014; 61(3): 538–543.
15. Chandra PK, Gunduz F, Hazari S et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 2014; 9(9): e108616.
16. Sulkowski MS, Eron JJ, Wyles D et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313(12): 1223–1231.
17. Testoni B, Durantel D, Lebosse F et al. Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 2015; epub ahead of print.
18. Mondelli MU. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? Hepatology 2014; 60(4): 1126–1129.
19. Feld JJ, Lutchman GA, Heller T et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139(1): 154–62 e4.
20. Werner JM, Serti E, Chepa-Lotrea X et al. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology 2014; 60(4): 1160–1169.
21. Kohli A, Osinusi A, Sims Z et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015; 385(9973): 1107–1113.
22. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6): 696–699.
23. Virtaneva K, Porcella SF, Graham MR et al. Longitudinal analysis of the group A Streptococcus transcriptome in experimental pharyngitis in cynomolgus macaques. Proc Natl Acad Sci USA 2005; 102(25): 9014–9019.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 1995; 57: 289–300.
25. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45(2): 164–171.
26. Testoni B, Levrero M, Durantel D. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? Gut 2014; 63(1): 3–4.
27. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, O'Farrelly C. Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 2011; 6(11): e27866.
28. Sedger LM. microRNA control of interferons and interferon induced anti-viral activity. Mol Immunol 2013; 56(4): 781–793.
29. Gantier MP. New perspectives in MicroRNA regulation of innate immunity. J Interferon Cytokine Res 2010; 30(5): 283–289.
30. Hou J, Lin L, Zhou W et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19(2): 232–243.
31. Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol 2012; 9(2): 137–142.
32. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122 – a key factor and therapeutic target in liver disease. J Hepatol 2015; 62(2): 448–457.
33. Baran-Gale J, Kurtz CL, Erdos MR, et al. Addressing bias in small RNA library preparation for sequencing: a new protocol recovers microRNAs that evade capture by current methods. Front Genet 2015; 6: 352.
34. Selitsky SR, Baran-Gale J, Honda M et al. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep 2015; 5: 7675.
35. Spaniel C, Honda M, Selitsky SR et al. microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS One 2013; 8(10): e76867.
36. Savan R. Post-transcriptional regulation of interferons and their signaling pathways. J Interferon Cytokine Res 2014; 34(5): 318–329.
37. McFarland AP, Horner SM, Jarret A et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15(1): 72–79.
38. Zhang X, Daucher M, Armistead D, Russell R, Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS One 2013; 8(2): e55733.
39. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2012; 86(18): 10221–10225.
40. Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 2014; 52(6): 445–451.
41. Singaravelu R, Russell RS, Tyrrell DL, Pezacki JP. Hepatitis C virus and microRNAs: miRed in a host of possibilities. Curr Opin Virol 2014; 7C: 1–10.
42. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013; 5(9): 479–486.
43. Chen Y, Chen J, Wang H et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013; 9(4): e1003248.
44. Li X, Yang W, Ye W, Jin L, He J, Lou L. microRNAs: Novel players in hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2014; 38(6): 664–675.
45. Pedersen IM, Cheng G, Wieland S et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449(7164): 919–922.
46. Cheng JC, Yeh YJ, Tseng CP et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012; 69(15): 2621–2633.
47. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50(3): 453–460.
48. Bandyopadhyay S, Friedman RC, Marquez RT et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis 2011; 203(12): 1753–1762.
49. Zhang Y, Wei W, Cheng N et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56(5): 1631–1640.
50. Onabajo OO, Porter-Gill P, Paquin A et al. Expression of interferon lambda 4 is associated with reduced proliferation and increased cell death in human hepatic cells. J Interferon Cytokine Res 2015; 35(11): 888–900.